Bertil Macao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bertil Macao has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Maria Falkenberg
University of Gothenburg
5 shared publications - Aleksandra Trifunovic
University of Cologne, Faculty of Medicine, Cluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), 50931 Cologne, Germany
3 shared publications - Carlo Viscomi
Veneto Institute of Molecular Medicine (VIMM), via Orus 2-35129 Padova, Italy
3 shared publications Massimo Zeviani
Department of Neurosciences, University of Padova, Via Belzoni 160, 35121, Padova, Italy
3 shared publications- Pedro Silva-Pinheiro
MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK
3 shared publications Raffaele Cerutti
Veneto Institute of Molecular Medicine (VIMM), Via Orus, 2-35129, Padova, Italy
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 9 (12) , e202503535
A selective inhibitor reveals roles for LONP1 in mitochondrial proteostasis and OXPHOS dependencies
Lon protease 1 (LONP1) is a conserved hexameric protease implicated in mitochondrial disorders and cancer progression. In this study, we present PZL-26, a potent and selective small-molecule inhibitor that targets LONP1 without affecting the proteasome, leading to selective accumulation of mitochondrial proteins. Using PZL-26 in a whole-genome CRISPR-Cas9 screen, we identified genes essential for cell survival under protease inhibition, supporting a role for LONP1 in key mitochondrial processes, including complex I biogenesis, mitochondrial transcription, and translation. Our CRISPR screen results are consistent with proteomics analysis, with both approaches converging on the same mitochondrial pathways and highlighting functional interactions between LONP1 and other mitochondrial proteases, including potential compensatory mechanisms. These findings establish PZL-26 as an effective tool for exploring LONP1 function and pave the way for future therapeutic strategies targeting LONP1 in mitochondrial diseases and cancer.
- 1 October 2026
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 9 (12) , e202503535
Open AccessA selective inhibitor reveals roles for LONP1 in mitochondrial proteostasis and OXPHOS dependencies
Lon protease 1 (LONP1) is a conserved hexameric protease implicated in mitochondrial disorders and cancer progression. In this study, we present PZL-26, a potent and selective small-molecule inhibitor that targets LONP1 without affecting the proteasome, leading to selective accumulation of mitochondrial proteins. Using PZL-26 in a whole-genome CRISPR-Cas9 screen, we identified genes essential for cell survival under protease inhibition, supporting a role for LONP1 in key mitochondrial processes, including complex I biogenesis, mitochondrial transcription, and translation. Our CRISPR screen results are consistent with proteomics analysis, with both approaches converging on the same mitochondrial pathways and highlighting functional interactions between LONP1 and other mitochondrial proteases, including potential compensatory mechanisms. These findings establish PZL-26 as an effective tool for exploring LONP1 function and pave the way for future therapeutic strategies targeting LONP1 in mitochondrial diseases and cancer.
- Open Access
- 6 July 2026
- Published by Oxford University Press (OUP) in NAR Molecular Medicine
- Vol. 3 (3)
SLIRP differentially modulates RNA binding of pathogenic LRPPRC variants
The LRPPRC/SLIRP complex is a key post-transcriptional regulator of mitochondrial gene expression, stabilizing mitochondrial mRNAs and promoting their polyadenylation and translation. Mutations in LRPPRC cause mitochondrial disorders, including Leigh syndrome French-Canadian type (LSFC), primarily affecting oxidative phosphorylation. Here, we examined the RNA-binding properties of wild-type LRPPRC and three pathogenic variants (A354V, K909del, and R1276_K1300del) using electrophoretic mobility shift assays, acoustic force spectroscopy, and AlphaFold 3 modeling. All three mutations reduced intrinsic RNA binding, with R1276_K1300del showing no detectable interaction in the absence of SLIRP. Remarkably, SLIRP restored RNA binding of this mutant to near wild-type levels, likely through conformational stabilization, as supported by single-molecule and structural analyses. These findings highlight SLIRP’s critical role in modulating LRPPRC function and suggest that enhancing SLIRP activity represents a potential therapeutic strategy for LRPPRC-related mitochondrial disorders.
- 6 July 2026
- Published by Oxford University Press (OUP) in NAR Molecular Medicine
- Vol. 3 (3)
Open AccessSLIRP differentially modulates RNA binding of pathogenic LRPPRC variants
The LRPPRC/SLIRP complex is a key post-transcriptional regulator of mitochondrial gene expression, stabilizing mitochondrial mRNAs and promoting their polyadenylation and translation. Mutations in LRPPRC cause mitochondrial disorders, including Leigh syndrome French-Canadian type (LSFC), primarily affecting oxidative phosphorylation. Here, we examined the RNA-binding properties of wild-type LRPPRC and three pathogenic variants (A354V, K909del, and R1276_K1300del) using electrophoretic mobility shift assays, acoustic force spectroscopy, and AlphaFold 3 modeling. All three mutations reduced intrinsic RNA binding, with R1276_K1300del showing no detectable interaction in the absence of SLIRP. Remarkably, SLIRP restored RNA binding of this mutant to near wild-type levels, likely through conformational stabilization, as supported by single-molecule and structural analyses. These findings highlight SLIRP’s critical role in modulating LRPPRC function and suggest that enhancing SLIRP activity represents a potential therapeutic strategy for LRPPRC-related mitochondrial disorders.
- Open Access
- 23 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 4782
Modelling POLG mutations in mice unravels a critical role of POLγΒ in regulating phenotypic severity
DNA polymerase γ (POLγ), responsible for mitochondrial DNA replication, consists of a catalytic POLγA subunit and two accessory POLγB subunits. Mutations in POLG, which encodes POLγA, lead to various mitochondrial diseases. We investigated the most common POLG mutations (A467T, W748S, G848S, Y955C) by characterizing human and mouse POLγ variants. Our data reveal that these mutations significantly impair POLγ activities, with mouse variants exhibiting milder defects. Cryogenic electron microscopy highlighted structural differences between human and mouse POLγ, particularly in the POLγB subunit, which may explain the higher activity of mouse POLγ and the reduced severity of mutations in mice. We further generated a panel of mouse models mirroring common human POLG mutations, providing crucial insights into the pathogenesis of POLG-related disorders and establishing robust models for therapeutic development. Our findings emphasize the importance of POLγB in modulating the severity of POLG mutations.
- 23 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 4782
Open AccessModelling POLG mutations in mice unravels a critical role of POLγΒ in regulating phenotypic severity
DNA polymerase γ (POLγ), responsible for mitochondrial DNA replication, consists of a catalytic POLγA subunit and two accessory POLγB subunits. Mutations in POLG, which encodes POLγA, lead to various mitochondrial diseases. We investigated the most common POLG mutations (A467T, W748S, G848S, Y955C) by characterizing human and mouse POLγ variants. Our data reveal that these mutations significantly impair POLγ activities, with mouse variants exhibiting milder defects. Cryogenic electron microscopy highlighted structural differences between human and mouse POLγ, particularly in the POLγB subunit, which may explain the higher activity of mouse POLγ and the reduced severity of mutations in mice. We further generated a panel of mouse models mirroring common human POLG mutations, providing crucial insights into the pathogenesis of POLG-related disorders and establishing robust models for therapeutic development. Our findings emphasize the importance of POLγB in modulating the severity of POLG mutations.
- Open Access
- 14 September 2021
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 49 (18) , 10803
Correction to ‘DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion’
The authors have accidentally used the same figure of a control mouse (Hematoxylin-eosin on liver sections) in Figure 3H and Supplementary Figure 4 of their article ( 1).
- 14 September 2021
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 49 (18) , 10803
Open AccessCorrection to ‘DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion’
The authors have accidentally used the same figure of a control mouse (Hematoxylin-eosin on liver sections) in Figure 3H and Supplementary Figure 4 of their article ( 1).
- Open Access
- 6 May 2021
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 49 (9) , 5230-5248
DNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion
Mutations in POLG, encoding POLγA, the catalytic subunit of the mitochondrial DNA polymerase, cause a spectrum of disorders characterized by mtDNA instability. However, the molecular pathogenesis of POLG-related diseases is poorly understood and efficient treatments are missing. Here, we generate the PolgA449T/A449T mouse model, which reproduces the A467T change, the most common human recessive mutation of POLG. We show that the mouse A449T mutation impairs DNA binding and mtDNA synthesis activities of POLγ, leading to a stalling phenotype. Most importantly, the A449T mutation also strongly impairs interactions with POLγB, the accessory subunit of the POLγ holoenzyme. This allows the free POLγA to become a substrate for LONP1 protease degradation, leading to dramatically reduced levels of POLγA in A449T mouse tissues. Therefore, in addition to its role as a processivity factor, POLγB acts to stabilize POLγA and to prevent LONP1-dependent degradation. Notably, we validated this mechanism for other disease-associated mutations affecting the interaction between the two POLγ subunits. We suggest that targeting POLγA turnover can be exploited as a target for the development of future therapies.
- 6 May 2021
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 49 (9) , 5230-5248
Open AccessDNA polymerase gamma mutations that impair holoenzyme stability cause catalytic subunit depletion
Mutations in POLG, encoding POLγA, the catalytic subunit of the mitochondrial DNA polymerase, cause a spectrum of disorders characterized by mtDNA instability. However, the molecular pathogenesis of POLG-related diseases is poorly understood and efficient treatments are missing. Here, we generate the PolgA449T/A449T mouse model, which reproduces the A467T change, the most common human recessive mutation of POLG. We show that the mouse A449T mutation impairs DNA binding and mtDNA synthesis activities of POLγ, leading to a stalling phenotype. Most importantly, the A449T mutation also strongly impairs interactions with POLγB, the accessory subunit of the POLγ holoenzyme. This allows the free POLγA to become a substrate for LONP1 protease degradation, leading to dramatically reduced levels of POLγA in A449T mouse tissues. Therefore, in addition to its role as a processivity factor, POLγB acts to stabilize POLγA and to prevent LONP1-dependent degradation. Notably, we validated this mechanism for other disease-associated mutations affecting the interaction between the two POLγ subunits. We suggest that targeting POLγA turnover can be exploited as a target for the development of future therapies.